文献リスト

1) Besarab A, Reyes CM, Hornberger J, et al. Metaanalysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kid Dis. 2002; 40: 439-46

2) Macdougall IC. Darbepoetin alfa: A new therapeutic agents for renal anemia. Kidney Int. 2002; 61(Suppl 80): S55-67

3) ネスプ静注用プラシリンジ-添付文書(2009年3月)

4) Fukuda N, Tanaka H, Tominaga Y, et al. Deceased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993; 92: 1436-43

5) Brown EM, Herbert SC. Ca2＋-receptor-mediated regulation of parathyroid and renal function. Am J Med Sci. 1996; 312: 99-109

6) Gogusev J, Duchambon P, Hory B, et al. Decreased expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997; 51: 328-36

7) Tominaga Y, Kohara S, Namii Y, et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg. 1996; 20: 744-52

8) Slatopolsky E, Weer C, Thielen J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxycholecalciferol in uremic patients. J Clin Invest. 1984; 74: 2136-43

9) 鈴木正司. Oral calcitriol pulse therapyによるmedicamentous parathyroidectomy. 腎と骨代謝. 1990; 3: 49-56

10) Kurikawa K, Akizawa T, Suzuki M, et al. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant. 1996; 11(Suppl 3): 121-4

11) Fukagawa M, Kitaoka M, Tominaga Y, et al. Selective percutaneous ethanol injection therapy(PEIT) of the parathyroid in chronic dialysis patients: the Japanese strategy. Nephrol Dial Transplant. 1999; 14: 2574-7

12) National Kidney Foundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kid Dis. 2003; 42(Suppl 3): S1-201

13) (社)日本透析医学会. 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌. 2006; 39: 1435-55

14) Brown EM, Hebert SC. Cloning and characterization of an cellular 2＋-sensing receptor from bovine parathyroid. Nature. 1993; 366: 575-80

15) Nemeth EM, Fox J. Calcimimetics compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trend in Endocrinol Metab. 1999; 10: 66-71

16) Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-25

17) Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005; 20: 2186-93

18) Fukagawa M, Yumita S, Akizawa T, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patints. Nephrol Dial Transplant. 2008; 23: 328-35

19) 秋澤忠男, 内田英二, 越川昭三, 他. 血液透析施行中の二次性副甲状腺機能亢進症患者に対するKRN1493(シナカルセト塩酸塩)長期投与の効果－長期投与試験(前期第Ⅱ相)－. 腎と透析. 2007; 63: 119-31

20) 鈴木正司, 秋澤忠男, 塚本雄介, 他. 二次性副甲状腺機能亢進症を伴う血液透析患者を対象としたKRN1493(シナカルセト塩酸塩)継続投与の効果. 腎と透析. 2009; 66: 869-81

21) 大森健太郎, 青池郁夫, 青柳春樹, 他. 透析皮膚掻痒症の実態－新潟県内41施設2474名の調査報告－. 透析会誌. 2001; 34: 1469-77

22) Pisoni RL, Wikstrom B, Elder SJ, et al. Pururitus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006; 21: 3495-505

23) 高森健二. 高齢者(老人性)皮膚掻痒症のかゆみ対策. 日本医事新報 2005; 4262: 1-7

24) 鈴木正司. 皮膚掻痒症. In: 中本雅彦, 佐中 孜, 秋澤忠男, 編. 透析療法事典. 第2版. 東京: 医学書院; 2009. p. 287-8

25) 熊谷裕生, 松川重明, 猿田亨男, 他. 維持血液透析患者のかゆみにおける内因性オピオイドの関与. 臨床薬理. 2000; 31: 457-8

26) Pauli-Magunas C, Mikus G, Mettang T, et al. Naltrexone dose not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol. 2000; 11: 514-9

27) Kumagai H, Utsumi J, Saruta T, et al. Prospect for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. In: Yosipovitch G. editor. Itch. Basic mechanisms and therapy. New York: Marcel Dekker; 2004. p. 279-86

28) レミッチ カプセル 2. 5μg. 添付文書(2009年3月)

29) Sullivan CM, Leon JB, Sehgal AR. Phosphorus containing food additives and the accuracy of nutrient database: implications for renal patients. J Ren Nutr. 2007; 17: 350-4

30) Sullivan CM, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease. JAMA. 2009; 11: 629-35

31) 鈴木正司. 腎性骨異栄養症におけるアルミニウムの役割. 第2回腎と骨代謝研究会記録. 1984; p. 59- 80

32) 中外製薬社内資料(2007年3月)

33) Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase Ⅲ study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kid Dis. 2003; 42: 96-107

34) Shigematsu T, The Lanthanum Carbonate Group: Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 2008; 70: 404-10

35) ホスレノールチュアブル錠. 市販直後調査(2009年7月)

36) Leeuw KD, Woestenburg A, Verbeelen A. Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh A liver cirrhosis. NDT Plus. 2008; 1: 412-3

37) Muller C, Chantrel F, Feller B. A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report. Nephrol Dial Transplant. 2009; 24: 3245-7

38) Pennick M, Dennis K, Damment SJP. Absolute bioavailability and disposition of lanthanum in healthy human subjects administerd lanthanum carbonate. J Clin Pharmacol. 2006; 46: 738-46

39) Damment SJP, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet. 2008; 47: 553-63

40) 吉田宗弘. 炭酸ランタン製剤経口投与後のランタンの組織分布について. Ther Res. 2009; 30: 971-4

41) Lacour B, Lucas A, Achere D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005; 67: 1062-9

42) Spasovski GB, Sikole A, Gelv S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006; 21: 2217-24

43) Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008; 110: c15-23

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp